ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.
- Author:
Chee Young KIM
1
;
Sang Hyuk SEO
;
Min Sung AN
;
Kwang Hee KIM
;
Ki Beom BAE
;
Jin Won HWANG
;
Ji Hyun KIM
;
Bo Mi KIM
;
Mi Seon KANG
;
Min Kyung OH
;
Kwan Hee HONG
Author Information
- Publication Type:Original Article
- Keywords: Colon neoplasms; FOLFOX; ERCC1
- MeSH: Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colon; Colonic Neoplasms; Disease-Free Survival; DNA Repair; Drug Therapy*; Female; Humans; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Retrospective Studies
- From:Annals of Coloproctology 2015;31(3):92-97
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients. METHODS: A total of 166 high risk stages II and III colon cancer patients were retrospectively enrolled in this study, and data were collected prospectively. They underwent a curative resection followed by FOLFOX4 adjuvant chemotherapy. We analyzed ERCC1 expression in the primary colon tumor by using immunohistochemical staining. The oncological outcomes included the 5-year disease-free survival (DFS) rate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model was used for the prognostic analysis. RESULTS: ERCC1-positive expression was statistically significant in the older patients (P = 0.032). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582). CONCLUSION: We found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.
